Delving into the Latest Updates on Halo Pharmaceutical Canada, Inc. with Synapse

Overview

主要目的是评估 Maralixibat 对胆道闭锁（BA）患者肝门肠吻合术（HPE）后胆道引流的有效性。次要目的为评估 Maralixibat 治疗后 sBA（血清胆汁酸）水平的变化，评估 Maralixibat 治疗后胆红素恢复正常的比率，评估 maralixibat 治疗后的无移植生存期，评估 Maralixibat 治疗后胆汁淤积和肝脏疾病的生化指标，以及评估Maralixibat 的安全性、耐受性和药代动力学。

[Translation]

The primary objective was to evaluate the effectiveness of maralixibat for biliary drainage after hepatoportoenterostomy (HPE) in patients with biliary atresia (BA). Secondary objectives were to evaluate changes in sBA (serum bile acid) levels after maralixibat treatment, to evaluate the rate of bilirubin normalization after maralixibat treatment, to evaluate transplant-free survival after maralixibat treatment, to evaluate biochemical markers of cholestasis and liver disease after maralixibat treatment, and to evaluate the safety, tolerability, and pharmacokinetics of maralixibat.

Start Date07 Jul 2022

Sponsor / Collaborator

Mirum Pharmaceuticals, Inc.

[+2]

100 Clinical Results associated with Halo Pharmaceutical Canada, Inc.

Login to view more data

0 Patents (Medical) associated with Halo Pharmaceutical Canada, Inc.

Login to view more data

100 Deals associated with Halo Pharmaceutical Canada, Inc.

Login to view more data

100 Translational Medicine associated with Halo Pharmaceutical Canada, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data